Trends Immunol. 2026 Aug 19:S1471-4906(26)00215-2. doi: 10.1016/j.it.2026.08.002. Online ahead of print.
ABSTRACT
The underlying mechanism of tumor microenvironment-induced dysfunction of conventional type 1 dendritic cells (cDC1) remains unclear. Zhang et al. identify transforming growth factor β-driven coactivator-associated arginine methyltransferase 1 (CARM1) as an epigenetic inhibitor of cDC1 cross-presentation. CARM1 is a cell-intrinsic brake, and its inhibition represents a multi-pronged tumor immunotherapy strategy.
PMID:42618461 | DOI:10.1016/j.it.2026.08.002